Exploitation of silicon medicinal chemistry in drug discovery

Expert Opinion on Investigational Drugs

Volumn 13, Issue 9, 2004, Pages 1149-1157

  Mills, John S ^a   Showell, Graham A ^a  

^a Amedis Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Drug discovery; Privileged structure; Silicon

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 4 [3,5 BIS(TRIMETHYLSILYL)BENZAMIDO]BENZOIC ACID; AGRICULTURAL CHEMICAL; ANTINEOPLASTIC AGENT; BUDIPINE; CAMPTOTHECIN DERIVATIVE; ELASTASE INHIBITOR; FLUSILAZOLE; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; KARENITECIN; NIGULDIPINE; ORGANOSILICON DERIVATIVE; PHTHALOCYANINE DERIVATIVE; PHYSOSTIGMINE; PIPERIDINE DERIVATIVE; PROTEINASE INHIBITOR; QUADROSILAN; SILABOLIN; SILAFUOFEN; SILICON DERIVATIVE; SILOXANE; SILPERISONE; TAC 101; TACRINE; UNCLASSIFIED DRUG; ZIFROSILONE;

ARTHRALGIA; BIOLOGY; BLOOD CLOT LYSIS; BRAIN CANCER; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DESIGN; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; FATIGUE; GENOMICS; HUMAN; HYPERTRIGLYCERIDEMIA; LIVER CANCER; LIVER TOXICITY; LUNG CANCER; MULTIGENE FAMILY; MUSCLE ATROPHY; MUSCLE SPASM; MYALGIA; NONHUMAN; ORGANIC CHEMISTRY; PARKINSON DISEASE; PHYSICAL CHEMISTRY; PRODUCTIVITY; PROSTATE CANCER; REVIEW; SIDE EFFECT; VALIDATION PROCESS;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; SILICON;

EID: 4544256139     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.9.1149     Document Type: Review

References (42)

1. DIMASI JA, HANSEN RW, GRABOWSKI HG, LASAGNA L: Cost of innovation in die pharmaceutical industry. Journal Health Econ. (1991) 10:107-142
2. DIMASI JA, HANSEN RW, GRABOWSKI HG: The price of innovation; new estimates of drug development costs. Journal Health Econ. (2003) 22:151-185
3. DREWS J: Strategic trends in the drug industry. Drug Discovery Today (2003) 8:411-420
4. HOPKINS AL, GROOM CR: The druggable genome. Nature Rev. Drug. Disc. (2002) 1(9):727-730
5. BOOTH B, ZEMMEL R: Quest for the best. Nature Rev. Drug. Disc. (2003) 2:838-841
6. SHOWELL GA, MILLS JS: Chemistry challenges in lead optimization: silicon isosteres in drug discovery. Drug Discov. Today (2003) 8(12):551-556
7. MITCHELL T, SHOWELL GA: Design strategies for building drug-like libraries. Curr. Opin. Drug Discov. Dev. (2001) 4:314-318
8. BAINS W, TACKE R: Silicon chemistry as a novel source of chemical diversity in drug design. Curr. Opin. Drug Discov. Dev. (2003) 6(4):526-543
9. TACKE R, WANNAGAT U: Synthesis and properties of bioactive organo-silicon compounds. Top. Curr. Chem. (1979) 84:1-75
10. REICHSTAT MM et al.: Theoretical investigation of intermolecular hydrogen-bonded complexes in systems: substituted carbinols (silanols) - ketones or ethers. J. Mol. Struct. (1991) 244:283-290
11. HOLTJE HD, BUSCH T: Theoretische untersuchungen an sila-analogen anticholinergika. Dtsch. Apoth. Ztg. (1986) 38:2007-2011
12. WOO DV, CHRISTIAN JE et al.: Pharmacological activity comparisons of barbiturates and their silicon analogues. Can. J. Pharm. Sci. (1979) 14:12-14
13. TACKE R, PIKIES J, LINOH H, ROHR-AEHLE R, GOENNE S: Sila-procyclidin: eine neue synthese sowie untersuchungen zur peripheren und zentralen anticholinergen wirkung. Liebigs Ann. Chem. (1987) (1):51-57
14. CLARK DE: In silice prediction of blood-brain barrier permeation. Drug Discov. Today (2003) 8(20):927-933
15. WA MUTAHI M, NITTOLI T, GUO L, SIEBURTH SM: Silicon-based metalloprotease inhibitors: synthesis and evaluation of silanol and silanediol peptide analogues as inhibitors of angiotensin-converting enzyme. J. Amer. Chem. Soc. (2002) 124(25):7363-7375
16. CHEN CA, SIEBURTH SM, GLEKAS A et al.: Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease. Chem. Biol. (2001) 8(12):1161-1166
17. COOPER JB: Aspartyl proteases in disease: a structural perspective. Curr. Drug Targets (2002) 3(2):155-173
18. PATCHETT AA, NARGUND RP: Privileged structures - an update. Ann. Rep. Med. Chem. (2000) 35:289-298
19. PATCHETT AA: 2002 Alfred Burger award address in medicinal chemistry. Natural products and design: interrelated approaches in drug discovery. J. Med. Chem. (2002) 45(26):5609-5616
20. LEUNG D, ABBENANTE G, FAIRLIE DP: Protease inhibitors: current status and future prospects. J. Med. Chem. (2000) 43(3):305-341
21. KURUP A, MEKAPATI SB, GARG R, HANSCH C: HIV-1 protease inhibitors: a comparative QSAR analysis. Curr. Med. Chem. (2003) 10(17):1679-1688
22. SIEBURTH SM, NITTOLI T, MUTAHI AM, GUO L: Silanediols: a new class of potent protease inhibitors. Angew. Chem. Int. Ed. (1998) 37:812-814
23. SOUTHAN C: A genome perspective on human proteases. FEBS Lett. (2001) 498:214-218
24. SOUTHAN C: A genome perspective on human proteases as drug targets. Drug Discov. Today (2001) 6(13):681-688
25. DAVEY J: G-protein-coupled receptors: new approaches to maximise the impact of GPCRs in drug discovery. Expert Opin. Ther. Targets (2004) 8(2):165-170
26. CHALMERS DT, BEHAN DP: The use of constitutively active GPCRs in drug discovery and functional genomics. Nature Rev. Drug. Disc. (2002) 1(8):599-608
27. BIRCH PJ, DEKKER LV, JAMES IF, SOUTHAN A, CRONK D: Strategies to identify ion channel modulators: current and novel approaches to target neuropathic pain. Drug Discov. Today (2004) 9(9):410-418
28. STASCH J-P, RUSS H, SCLACHT U et al.: 4,4-Diphenylpiperidine derivatives and their sila analogues. Arzneim.-Forsch./Drug Res. (1988) 38(II)(8):1075-1078
29. 2+ channel antagonist niguldipine. J. Med. Chem. (1995) 38(10):1579-1581
30. 1 adrenoceptor antagonists of the silaniguldipine type. Organometallics (2004) 23(3):361-366
31. GARSON LR, KIRCHNER LK: Organosilicon entities as prophylactic and therapeutic agents. J. Pharm. Sci. (1971) 60:1113-1127
32. FARKAS S, KOCSIS P, BIELIK N, GÉMESI L, TRAFIKÂNT G: Analysis of the mechanism of action, relationship between pharmacodynamics and pharmacokinetics of silperisone, a new centrally acting muscle relaxant. Fundam. Clin. Pharmacol. (1999) 13(1):PS144
33. BRUFANI M, FILOCAMO L, LAPPA S, MAGGI A: New acetylcholinesterase inhibitors. Drug Future (1997) 22(4):397-410
34. CUTLER NR, SEIFERT RD, SCHLEMAN MM et al.: Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. (1995) 58(1):54-61
35. PALAZZOLO RJ, McHARD JA, HOBBS EJ, FANCHER OE, CALANDRA JC: Investigation of the toxicologic properties of a phenylmethylcyclosiloxane. Toxicol. Appl. Pharmacol. (1972) 21:15-28
36. ALFTHAN O, ANDERSSON L, ESPOSTI PL et al.: Cisobitan in treatment of prostatic cancer. A prospective controlled multicentre study. Stand. J. Uron. Nephrol. (1983) 17(1):37-43
37. COLLSTE L, BERLIN T, VON GARRELTS B, GRANBERG I, LEWANDER R: Clinical trial of a new antigonadotropic substance, 2,6-cis-diphenylhexamethylcyclotetrasiloxane, in cancer of the prostate. A pilot study. Eur. Urol. (1981) 7(2):85-88
38. ANDERSON CY, FREYE K, TUBESING KA et al.: A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumours inC3H mice. Photochem. Photobiol. (2004) 67(3):332-336
39. KURIE J, HONG WK, KHURI F et al.: A dose-escalation, pharmacokinetic and safety study of oral TAC-101 inpatients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. (2000) 19:749
40. RIZVI NA, MARSHALL JL, NESS E et al.: Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-α selective retinoid, in patients with advanced cancer. J. Clin. Oncol. (2002) 20(16 ):3522-3532
41. SCHILSKY R, HAUSHEER F, BERTUCCI D, BERGHORN E, KINDLER H, RATAIN M: Phase I trial of karenitecin (KT) administered intravenously daily for five consecutive days in patients with advance solid tumours using accelerated dose titration. Proc. Am. Soc. Clin. Oncol. (2000) 19:758
42. BURRILL GS: Drug Discovery World, Winter 2003/2004, 9-11